Published in Vaccine Weekly, July 24th, 2002
The new agreement covers work performed for all of Pfizer's global research and development sites worldwide.
ViroLogic has developed technologies to assess drug resistance among a number of antiretroviral therapies in both preclinical and clinical studies including PhenoSense HIV, GeneSeq, PhenoSenseGT, PhenoSense HIV Entry, and PhenoScreen.
"This expanded agreement highlights how ViroLogic can serve as the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.